KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Quest Diagnostics (DGX) EBITDA: 2009-2024

Historic EBITDA for Quest Diagnostics (DGX) over the last 16 years, with Dec 2024 value amounting to $1.3 billion.

  • Quest Diagnostics' EBITDA rose 16.97% to $386.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 22.28%. This contributed to the annual value of $1.3 billion for FY2024, which is 6.66% up from last year.
  • Quest Diagnostics' EBITDA amounted to $1.3 billion in FY2024, which was up 6.66% from $1.3 billion recorded in FY2023.
  • Quest Diagnostics' 5-year EBITDA high stood at $2.4 billion for FY2021, and its period low was $1.3 billion during FY2023.
  • Its 3-year average for EBITDA is $1.3 billion, with a median of $1.3 billion in 2024.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 60.11% in 2020, then tumbled by 40.03% in 2022.
  • Over the past 5 years, Quest Diagnostics' EBITDA (Yearly) stood at $2.0 billion in 2020, then climbed by 20.80% to $2.4 billion in 2021, then slumped by 40.03% to $1.4 billion in 2022, then decreased by 11.62% to $1.3 billion in 2023, then grew by 6.66% to $1.3 billion in 2024.